|
|
|
Volumn 4, Issue 2, 2008, Pages 321-336
|
|
Review of the clinical evidence for interferon β la (Rebif®) in the treatment of multiple sclerosis
a
|
|
Author keywords
Clinical trials; Interferon 1a; Multiple sclerosis; Post marketing studies; Review
|
|
Indexed keywords
BETA1A INTERFERON;
BOVINE SERUM ALBUMIN;
GADOLINIUM;
GLATIRAMER;
HUMAN SERUM ALBUMIN;
INTERFERON BETA SERINE;
NEUTRALIZING ANTIBODY;
PLACEBO;
STEROID;
ABNORMAL LABORATORY RESULT;
ANGIONEUROTIC EDEMA;
ANTIBODY DETECTION;
ANTIINFLAMMATORY ACTIVITY;
ANTIVIRAL ACTIVITY;
AUTOIMMUNITY;
CLINICAL EFFECTIVENESS;
CLINICAL TRIAL;
CONTRAST ENHANCEMENT;
CYTOKINE PRODUCTION;
DISABILITY;
DISEASE ACTIVITY;
DISEASE COURSE;
DISEASE SEVERITY;
DOSAGE SCHEDULE COMPARISON;
DOSE RESPONSE;
DRUG DOSE COMPARISON;
DRUG EFFICACY;
DRUG FEVER;
DRUG FORMULATION;
DRUG INDUCED HEADACHE;
DRUG MEGADOSE;
DRUG SAFETY;
DRUG STRUCTURE;
DRUG SUBSTITUTION;
DRUG TOLERABILITY;
DRUG TREATMENT FAILURE;
DRUG WITHDRAWAL;
EARLY INTERVENTION;
FATIGUE;
FLU LIKE SYNDROME;
GRANULOCYTOPENIA;
HEMATOLOGIC DISEASE;
HUMAN;
IMMUNOGENICITY;
IMMUNOMODULATION;
INJECTION SITE REACTION;
LEUKOPENIA;
LONG TERM EXPOSURE;
LOW DRUG DOSE;
LYMPHOCYTOPENIA;
MULTIPLE SCLEROSIS;
MYALGIA;
NEUROPROTECTION;
NONHUMAN;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PATIENT COMPLIANCE;
POSTMARKETING SURVEILLANCE;
RECURRENCE RISK;
RECURRENT DISEASE;
REVIEW;
RISK ASSESSMENT;
RISK REDUCTION;
SIDE EFFECT;
SKIN NECROSIS;
T LYMPHOCYTE ACTIVATION;
THYROID DISEASE;
TREATMENT RESPONSE;
URTICARIA;
|
|
EID: 44049094579
PISSN: 11766328
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (27)
|
|
References (95)
|
